Explore

Trendline Trendline
Bayer to Acquire Perfuse Therapeutics in $2.45 Billion Deal to Enhance Ophthalmology Pipeline

Bayer to Acquire Perfuse Therapeutics in $2.45 Billion Deal to Enhance Ophthalmology Pipeline

Bayer to Acquire Perfuse Therapeutics in $2.45 Billion Deal to Enhance Ophthalmology Pipeline
Trendline Trendline
Bayer's $2.45 Billion Acquisition of Perfuse Therapeutics Aims to Revolutionize Eye Disease Treatment

Bayer's $2.45 Billion Acquisition of Perfuse Therapeutics Aims to Revolutionize Eye Disease Treatment

Bayer's $2.45 Billion Acquisition of Perfuse Therapeutics Aims to Revolutionize Eye Disease Treatment
Trendline Trendline
Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables
Trendline Trendline
SAB Biotherapeutics Enters $36 Million Manufacturing Agreement for SAB-142 with Emergent BioSolutions

SAB Biotherapeutics Enters $36 Million Manufacturing Agreement for SAB-142 with Emergent BioSolutions

SAB Biotherapeutics Enters $36 Million Manufacturing Agreement for SAB-142 with Emergent BioSolutions
Trendline Trendline
Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept
Trendline Trendline
UCB to Acquire Candid Therapeutics for $2.2 Billion, Expanding TCE Antibody Portfolio

UCB to Acquire Candid Therapeutics for $2.2 Billion, Expanding TCE Antibody Portfolio

UCB to Acquire Candid Therapeutics for $2.2 Billion, Expanding TCE Antibody Portfolio
Trendline Trendline
Pharmaceutical Leaders Utilize Protein Biomarkers to Mitigate Drug Development Risks

Pharmaceutical Leaders Utilize Protein Biomarkers to Mitigate Drug Development Risks

Pharmaceutical Leaders Utilize Protein Biomarkers to Mitigate Drug Development Risks
Trendline Trendline
Takeda's TAK-881 Shows Promising Results in Phase 2/3 Trial for Primary Immunodeficiency Disease

Takeda's TAK-881 Shows Promising Results in Phase 2/3 Trial for Primary Immunodeficiency Disease

Takeda's TAK-881 Shows Promising Results in Phase 2/3 Trial for Primary Immunodeficiency Disease
Trendline Trendline
GSK Licenses siRNA Drug from China's SiranBio in $1 Billion Deal to Target Cardiometabolic Diseases

GSK Licenses siRNA Drug from China's SiranBio in $1 Billion Deal to Target Cardiometabolic Diseases

GSK Licenses siRNA Drug from China's SiranBio in $1 Billion Deal to Target Cardiometabolic Diseases
Trendline Trendline
Arrowhead Pharmaceuticals Licenses MASH Program to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals Licenses MASH Program to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals Licenses MASH Program to Madrigal Pharmaceuticals
Trendline Trendline
Epirium Bio Unveils Promising Preclinical Data on 15-PGDH Inhibitors for Inflammatory Bowel Disease

Epirium Bio Unveils Promising Preclinical Data on 15-PGDH Inhibitors for Inflammatory Bowel Disease

Epirium Bio Unveils Promising Preclinical Data on 15-PGDH Inhibitors for Inflammatory Bowel Disease
Trendline Trendline
Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results

Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results

Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results